CAR-T-Zell-Therapie Logo
  • Aktuelles
  • Studien
  • Zentren
  • Patient:inneninfos
  • Fortbildung
  • Zulassungen
  • Fachbeiträge
  • Community
  • Login
Suche
zurück zur Zentren Übersicht
Niedersachsen

Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Zelltherapie

Carl-Neuberg-Str. 1
D-30625 Hannover
Leitung: Prof. Dr. med. Florian Heidel

Studien

  • INTEGRATE ATMP
  • A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
  • A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  • Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
  • Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) (CYTORELEASE)
  • A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX
  • A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Kontakt

PD Dr. med. Christian Schultze-Florey
Leitung CAR T-Zell Programm
CART@mh-hannover.de
+49 511 532-3022

Studien

  • INTEGRATE ATMP
  • A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
  • A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  • Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
  • Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) (CYTORELEASE)
  • A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX
  • A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
  • Aktuelles
  • Studien
  • Zentren
  • Patient:inneninfos
  • Fortbildung
  • Fachbeiträge
  • Zulassungen
  • Community
  • CARTakut
  • Aktuelles
  • Studien
  • Zentren
  • Patient:inneninfos
  • Fortbildung
  • Fachbeiträge
  • Zulassungen
  • Community
  • CARTakut
Ein Projekt von:
In Zusammenarbeit mit:
© MedMedia Verlag und Mediaservice GmbH - Seidengasse 9/Top 1.1, 1070 Wien - Tel.: +43 1 4073111-0 - Fax: +43 1 4073114
  • Impressum
  • Kontakt
  • Datenschutz
  • Cookie Einstellungen